divestiture
Hutchmed Submits NDA in China for Orpathys, Tagrisso Combo in EGFR, MET-Driven NSCLC
The firm also announced that it was divesting most of its equity interest in Shanghai Hutchison Pharmaceuticals to invest in its own pipeline.
The firm also announced that it was divesting most of its equity interest in Shanghai Hutchison Pharmaceuticals to invest in its own pipeline.